Clinical Trial Update: Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating short-course rifamycin-based regimens for latent tuberculosis in patients with end-stage kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease
• Latent Tuberculosis

Drugs mentioned

• rifamycin-based regimens (rifamycin)

Snippet

Sponsor: Miguel Santín | Conditions: Latent Tuberculosis, Kidney Failure | Phase 4 | Status: UNKNOWN